The FDA granted marketing clearance for Cytokinetics’ aficamten (Myqorzo) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM), making a daily oral myosin inhibitor available to patients. Myqorzo’s approval creates a direct competitive dynamic with Bristol Myers Squibb’s Camzyos; analysts note differences in monitoring and safety restrictions that could shape uptake. The label carries a boxed warning on systolic dysfunction and heart‑failure risk. Cytokinetics will now commercialize a first‑time approval in its company history and position Myqorzo against an established entrant. Cardiomyopathy specialists will evaluate relative efficacy, safety monitoring needs and real‑world tolerability as both products compete for the same patient population.